Cargando…
Anti-RANKL treatment inhibits erosive joint destruction and lowers inflammation but has no effect on bone formation in the delayed-type hypersensitivity arthritis (DTHA) model
BACKGROUND: The aims of the present study were to determine the relationship between bone destruction and bone formation in the delayed-type hypersensitivity arthritis (DTHA) model and to evaluate the effect of receptor activator of nuclear factor κB ligand (RANKL) blockade on severity of arthritis,...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4724155/ https://www.ncbi.nlm.nih.gov/pubmed/26801240 http://dx.doi.org/10.1186/s13075-016-0931-3 |
_version_ | 1782411542919118848 |
---|---|
author | Atkinson, Sara Marie Bleil, Janine Maier, René Kühl, Anja A. Thorn, Mette Serikawa, Kyle Fox, Brian Kruse, Kim Haase, Claus Skov, Søren Nansen, Anneline Syrbe, Uta |
author_facet | Atkinson, Sara Marie Bleil, Janine Maier, René Kühl, Anja A. Thorn, Mette Serikawa, Kyle Fox, Brian Kruse, Kim Haase, Claus Skov, Søren Nansen, Anneline Syrbe, Uta |
author_sort | Atkinson, Sara Marie |
collection | PubMed |
description | BACKGROUND: The aims of the present study were to determine the relationship between bone destruction and bone formation in the delayed-type hypersensitivity arthritis (DTHA) model and to evaluate the effect of receptor activator of nuclear factor κB ligand (RANKL) blockade on severity of arthritis, bone destruction, and bone formation. METHODS: DTHA was induced in C57BL/6 mice. Inflammation, erosive joint damage, and new bone formation were semiquantitatively scored by histology. Osteoclast activity was assessed in vivo, and messenger RNA (mRNA) expression of mediators of bone destruction and bone formation were analyzed by mRNA deep sequencing. Serum concentrations of tartrate-resistant acid phosphatase 5b, carboxy-terminal telopeptide I (CTX-I), matrix metalloproteinase 3 (MMP3), and serum amyloid P component (SAP) were determined by enzyme-linked immunosorbent assay. Anti-RANKL monoclonal antibody treatment was initiated at the time of immunization. RESULTS: Bone destruction (MMP3 serum levels, cathepsin B activity, and RANKL mRNA) peaked at day 3 after arthritis induction, followed by a peak in cartilage destruction and bone erosion on day 5 after arthritis induction. Periarticular bone formation was observed from day 10. Induction of new bone formation indicated by enhanced Runx2, collagen X, osteocalcin, MMP2, MMP9, and MMP13 mRNA expression was observed only between days 8 and 11. Anti-RANKL treatment resulted in a modest reduction in paw and ankle swelling and a reduction of serum levels of SAP, MMP3, and CTX-I. Destruction of the subchondral bone was significantly reduced, while no effect on bone formation was seen. CONCLUSIONS: Anti-RANKL treatment prevents joint destruction but does not prevent new bone formation in the DTHA model. Thus, although occurring sequentially during the course of DTHA, bone destruction and bone formation are apparently not linked in this model. |
format | Online Article Text |
id | pubmed-4724155 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-47241552016-01-24 Anti-RANKL treatment inhibits erosive joint destruction and lowers inflammation but has no effect on bone formation in the delayed-type hypersensitivity arthritis (DTHA) model Atkinson, Sara Marie Bleil, Janine Maier, René Kühl, Anja A. Thorn, Mette Serikawa, Kyle Fox, Brian Kruse, Kim Haase, Claus Skov, Søren Nansen, Anneline Syrbe, Uta Arthritis Res Ther Research Article BACKGROUND: The aims of the present study were to determine the relationship between bone destruction and bone formation in the delayed-type hypersensitivity arthritis (DTHA) model and to evaluate the effect of receptor activator of nuclear factor κB ligand (RANKL) blockade on severity of arthritis, bone destruction, and bone formation. METHODS: DTHA was induced in C57BL/6 mice. Inflammation, erosive joint damage, and new bone formation were semiquantitatively scored by histology. Osteoclast activity was assessed in vivo, and messenger RNA (mRNA) expression of mediators of bone destruction and bone formation were analyzed by mRNA deep sequencing. Serum concentrations of tartrate-resistant acid phosphatase 5b, carboxy-terminal telopeptide I (CTX-I), matrix metalloproteinase 3 (MMP3), and serum amyloid P component (SAP) were determined by enzyme-linked immunosorbent assay. Anti-RANKL monoclonal antibody treatment was initiated at the time of immunization. RESULTS: Bone destruction (MMP3 serum levels, cathepsin B activity, and RANKL mRNA) peaked at day 3 after arthritis induction, followed by a peak in cartilage destruction and bone erosion on day 5 after arthritis induction. Periarticular bone formation was observed from day 10. Induction of new bone formation indicated by enhanced Runx2, collagen X, osteocalcin, MMP2, MMP9, and MMP13 mRNA expression was observed only between days 8 and 11. Anti-RANKL treatment resulted in a modest reduction in paw and ankle swelling and a reduction of serum levels of SAP, MMP3, and CTX-I. Destruction of the subchondral bone was significantly reduced, while no effect on bone formation was seen. CONCLUSIONS: Anti-RANKL treatment prevents joint destruction but does not prevent new bone formation in the DTHA model. Thus, although occurring sequentially during the course of DTHA, bone destruction and bone formation are apparently not linked in this model. BioMed Central 2016-01-23 2016 /pmc/articles/PMC4724155/ /pubmed/26801240 http://dx.doi.org/10.1186/s13075-016-0931-3 Text en © Atkinson et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Atkinson, Sara Marie Bleil, Janine Maier, René Kühl, Anja A. Thorn, Mette Serikawa, Kyle Fox, Brian Kruse, Kim Haase, Claus Skov, Søren Nansen, Anneline Syrbe, Uta Anti-RANKL treatment inhibits erosive joint destruction and lowers inflammation but has no effect on bone formation in the delayed-type hypersensitivity arthritis (DTHA) model |
title | Anti-RANKL treatment inhibits erosive joint destruction and lowers inflammation but has no effect on bone formation in the delayed-type hypersensitivity arthritis (DTHA) model |
title_full | Anti-RANKL treatment inhibits erosive joint destruction and lowers inflammation but has no effect on bone formation in the delayed-type hypersensitivity arthritis (DTHA) model |
title_fullStr | Anti-RANKL treatment inhibits erosive joint destruction and lowers inflammation but has no effect on bone formation in the delayed-type hypersensitivity arthritis (DTHA) model |
title_full_unstemmed | Anti-RANKL treatment inhibits erosive joint destruction and lowers inflammation but has no effect on bone formation in the delayed-type hypersensitivity arthritis (DTHA) model |
title_short | Anti-RANKL treatment inhibits erosive joint destruction and lowers inflammation but has no effect on bone formation in the delayed-type hypersensitivity arthritis (DTHA) model |
title_sort | anti-rankl treatment inhibits erosive joint destruction and lowers inflammation but has no effect on bone formation in the delayed-type hypersensitivity arthritis (dtha) model |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4724155/ https://www.ncbi.nlm.nih.gov/pubmed/26801240 http://dx.doi.org/10.1186/s13075-016-0931-3 |
work_keys_str_mv | AT atkinsonsaramarie antirankltreatmentinhibitserosivejointdestructionandlowersinflammationbuthasnoeffectonboneformationinthedelayedtypehypersensitivityarthritisdthamodel AT bleiljanine antirankltreatmentinhibitserosivejointdestructionandlowersinflammationbuthasnoeffectonboneformationinthedelayedtypehypersensitivityarthritisdthamodel AT maierrene antirankltreatmentinhibitserosivejointdestructionandlowersinflammationbuthasnoeffectonboneformationinthedelayedtypehypersensitivityarthritisdthamodel AT kuhlanjaa antirankltreatmentinhibitserosivejointdestructionandlowersinflammationbuthasnoeffectonboneformationinthedelayedtypehypersensitivityarthritisdthamodel AT thornmette antirankltreatmentinhibitserosivejointdestructionandlowersinflammationbuthasnoeffectonboneformationinthedelayedtypehypersensitivityarthritisdthamodel AT serikawakyle antirankltreatmentinhibitserosivejointdestructionandlowersinflammationbuthasnoeffectonboneformationinthedelayedtypehypersensitivityarthritisdthamodel AT foxbrian antirankltreatmentinhibitserosivejointdestructionandlowersinflammationbuthasnoeffectonboneformationinthedelayedtypehypersensitivityarthritisdthamodel AT krusekim antirankltreatmentinhibitserosivejointdestructionandlowersinflammationbuthasnoeffectonboneformationinthedelayedtypehypersensitivityarthritisdthamodel AT haaseclaus antirankltreatmentinhibitserosivejointdestructionandlowersinflammationbuthasnoeffectonboneformationinthedelayedtypehypersensitivityarthritisdthamodel AT skovsøren antirankltreatmentinhibitserosivejointdestructionandlowersinflammationbuthasnoeffectonboneformationinthedelayedtypehypersensitivityarthritisdthamodel AT nansenanneline antirankltreatmentinhibitserosivejointdestructionandlowersinflammationbuthasnoeffectonboneformationinthedelayedtypehypersensitivityarthritisdthamodel AT syrbeuta antirankltreatmentinhibitserosivejointdestructionandlowersinflammationbuthasnoeffectonboneformationinthedelayedtypehypersensitivityarthritisdthamodel |